CD36 and metabolic dysfunction-associated steatotic liver disease: It has been shown that levels of CD36 are higher in patients with NAFLD than in normal subjects, pointing to a potential role of CD36 in lipid metabolism; consequently, its transcriptional regulators pathways are considered therapeutic targets for treating NAFLD (Mundi et al. 2020).